DRI Healthcare TrustDHTRF 33 PB Ratio is 1.61 as of Jul. 04, 2026, which is 79% above its 10-year median of 0.90. GuruFocus rates DHTRF with a GF Score™ of 33/100 and a GF Value™ of $13.28 (Fairly Valued). The stock has 4 warning signs investors should review. Among 921 Drug Manufacturers companies, DRI Healthcare Trust ranks better than 58.63% on this metric.
DRI Healthcare Trust stock PB Ratio (=1.56) is close to 5-year high of 1.63.
The historical rank and industry rank for DRI Healthcare Trust's PB Ratio or its related term are showing as below:
DHTRF'
s PB Ratio Range Over the Past 10 Years
Min: 0.48 Med: 0.9 Max: 1.63
Current: 1.56
During the past 5 years, DRI Healthcare Trust's highest PB Ratio was 1.63. The lowest was 0.48. And the median was 0.90.
DHTRF's PB Ratio is ranked better than 58.63% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs DHTRF: 1.56
During the past 12 months, DRI Healthcare Trust's average Book Value Per Share Growth Rate was -14.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -6.90% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of DRI Healthcare Trust was -1.10% per year. The lowest was -6.90% per year. And the median was -4.00% per year.
Back to Basics: PB Ratio
DRI Healthcare Trust (OTCPK:DHTRF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
DRI Healthcare Trust PB Ratio Related Terms
DRI Healthcare Trust PB Ratio Historical Data
* Premium members only.
The historical data trend for DRI Healthcare Trust's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DRI Healthcare Trust's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DRI Healthcare Trust PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DRI Healthcare Trust's PB Ratio distribution charts can be found below:
* The bar in red indicates where DRI Healthcare Trust's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
DRI Healthcare Trust (DHTRF) has a PB Ratio of 1.61 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on DRI Healthcare Trust and its competitors. This is 79% above median its historical median of 0.90. Over the past decade, DRI Healthcare Trust's PB Ratio has ranged from 0.48 to 1.63. According to the industry distribution chart, DRI Healthcare Trust ranks #381 out of 921 companies in the Drug Manufacturers industry, placing it in the top 41.4%.
Is DRI Healthcare Trust's PB Ratio too high?
DRI Healthcare Trust's current PB Ratio of 1.61 is 79% above median its 10-year median of 0.90. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 1.63. The Drug Manufacturers industry median PB Ratio is 1.91. DRI Healthcare Trust's value of 1.61 is 15.7% below this industry median. Based on the distribution chart, DRI Healthcare Trust ranks #381 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, DRI Healthcare Trust has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DRI Healthcare Trust's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, DRI Healthcare Trust ranks #381 out of 921 companies for PB Ratio. This puts DRI Healthcare Trust in the upper half of its industry. The industry median PB Ratio is 1.91. DRI Healthcare Trust's value of 1.61 is 15.7% below this benchmark. Historically, DRI Healthcare Trust's own PB Ratio has ranged from 0.48 to 1.63 over the past decade. While the company's 10-year median is 0.90 vs. the industry median of 1.91, DRI Healthcare Trust has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DRI Healthcare Trust's current PB Ratio of 1.61 is 15.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on DRI Healthcare Trust and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DRI Healthcare Trust's current PB Ratio is 1.61, which is 79% above median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DRI Healthcare Trust stock overvalued right now?
Based on GuruFocus' analysis, DRI Healthcare Trust (DHTRF) is currently considered Fairly Valued. The stock's GF Value™ is $13.28, compared to a current price of $12.70 — trading 4.4% below its estimated fair value. The current PB Ratio is 1.61, which is 79% above median its 10-year median of 0.90 and 15.7% below the Drug Manufacturers industry median of 1.91. DRI Healthcare Trust's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For DRI Healthcare Trust (DHTRF), the current PB Ratio is 1.61 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DRI Healthcare Trust (DHTRF) Overvalued in 2026?
Based on GuruFocus' analysis, DRI Healthcare Trust stock appears to be undervalued.
The current stock price of $12.70 is trading 4.4% below its estimated GF Value™ of $13.28.
GuruFocus considers DRI Healthcare Trust to be Fairly Valued.
Key valuation signals for DHTRF:
PB Ratio: 1.61 (79% above median its 10-year median of 0.90)
GF Value™: $13.28 vs. price of $12.70 (4.4% below fair value)
Industry Position: 15.7% below the Drug Manufacturers median (#381 of 921)
No single metric tells the full story. See the DHTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DRI Healthcare Trust is an open-ended trust that purchases royalty entitlements on products that address unmet medical needs, providing its unitholders with top-line exposure to a portfolio of therapeutics. Its portfolio comprises several royalty streams on products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, as well as lysosomal storage disorders (LSD) and immunology. The Trust has concluded that it operates as one segment, focused on acquiring royalty assets. Geographically, it generates maximum royalty income from the sale of products underlying its royalty agreements in the United States, followed by other markets such as Japan, the European Union, and the rest of the world.
33GF Score
Get the complete analysis for DHTRF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHTRF has been successfully added to your 
